AstraZeneca looks to CRISPR to boost success rates

Between 2005 and 2010 AstraZeneca‘s success rates for taking drugs from candidate nomination to phase III completion were at 4%, below an already-low industry standard of 5%. As Mene Pangalos, the company’s executive vice president, Innovative Medicines & Early Development (IMED) Biotech Unit, puts it, AstraZeneca and the industry as a whole are “good at failing”.